Dou­bling down on the Keytru­da fran­chise, Mer­ck pays $300M and promis­es $5B-plus to part­ner with Ei­sai on its bud­ding can­cer star

Im­pressed by the po­ten­tial of a com­bo fea­tur­ing Keytru­da with Ei­sai’s star can­cer drug Lenvi­ma (lenva­tinib me­sy­late), Mer­ck $MRK has stepped up with $300 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER